Table 3.
Positive rates of targeted diagnostic antibodies in different types of CUP predicted to have a similar tissue origin and corresponding primary tumor
| Predicted primary tumor site# | IHC antibody | Positive rate in CUP tumor | Positive rate in primary tumor |
|---|---|---|---|
| Breast | GATA3 | 57.8% (26/45) | ~ 90%[32] |
| Mammaglobin | 16.0% (4/25) | 60-80%[32] | |
| GCDFP15 | 25.8 (8/31) | 60%─80%[32] | |
| SOX10 | 69.2% (9/13) | ~ 70%[42] | |
| TRPS1 | 75.0% (9/12) | ~ 90%[33] | |
| Colorectum | CK7 | 63.2% (12/19) | ~ 40%[43] |
| CK20 | 85.0% (17/20) | 60─100%[43] | |
| CDX2 | 50.0% (6/12) | 80─90%[32] | |
| SATB2 | 62.5% (5/8) | 80─90%[32] | |
| Gastroesophagus | CK7 | 90.9% (20/22) | 40─70%[43] |
| CK20 | 44.4% (8/19) | 30─50%[43] | |
| CK19 | 88.9% (8/9) | ~ 90%[44] | |
| CDX2 | 33.3% (5/15) | ~ 30%[32] | |
| Lung | CK7 | 88.0% (22/25) | > 90%[43] |
| NapsinA | 25.0% (3/12) | 60–80%[32] | |
| TTF1 | 42.1% (8/19) | 70─90%[32] | |
| Pancreas | CK7 | 100.0% (10/10) | 80─100%[43] |
| CK19 | 100.0% (8/8) | ~ 90%[44] | |
| SMAD4 loss | 62.5% (5/8) | 60%[45] | |
| Ovary | PAX8 | 75.0% (12/16) | ~ 90%[32] |
| WT1 | 66.7% (8/12) | ~ 90%[32] | |
| ER | 23.1% (3/13) | ~ 75%[32] | |
| Urinary | GATA3 | 70.0% (7/10) | ~ 80%[32] |
| CK7 | 84.6% (11/13) | ~ 80─90%[43] | |
| Kidney | PAX8 | 100.0% (4/4) | > 80%[32] |
| Vimentin | 75.0% (3/4) | > 80%[46] |
#Predicted primary tumor site was decided by the combination of clinical investigations, clinicopathological data and molecular testing